Researchers dicover novel targets for rheumatoid arthritis therapies
Researchers have identified that autoreactive B cells and a protein that enables them to invade joints could be promising drug targets for the most common inflammatory arthritis.
List view / Grid view
Researchers have identified that autoreactive B cells and a protein that enables them to invade joints could be promising drug targets for the most common inflammatory arthritis.
The molecular structure of the SARS-CoV-2 Envelope protein has been identified by researchers using nuclear magnetic resonance.
A specific furin cleavage motif on the SARS-CoV-2 Spike protein, not present on other coronaviruses (CoVs), could be targeted by novel COVID-19 therapies.
Pre-clinical studies have shown that the TJ210/MOR210 monoclonal antibody is successful at targeting tumours.
Reports suggest the market growth is driven by advances in biotechnology and its applications, as well as COVID-19 research.
Researchers have shown that the internal clock controls the regenerative mechanism behind beta cells in diabetic mice.
Researchers have found bioengineering CHO cells using CRISPR-Cas9 can decrease the secretion of metabolic by-products that hinder growth.
The semi-automated process enabled researchers to make retinal organoid production and selection nearly four times faster.
The synthetic protein nanoparticle can cross the blood-brain barrier and deliver a targeted therapeutic to glioblastoma cells, say researchers.
The SARS-CoV-2 RNA genome structure has been studied by researchers who identified several potential drug targets.
A new single-use, closed-system upstream bioprocess has been developed which enables the production of large number of haematopoietic stem cells and progenitor cells.
Using their de novo protein design strategy, researchers engineered human angiotensin converting enzyme 2 (hACE2) protein decoys that can protect cells from SARS-CoV-2 infection.
Scientists have developed a new antibody-drug conjugate (ADC), made from ICAM1, an antibody that targets pancreatic cancer and the cytotoxic drug DM1 (mertansine).
After viral pneumonia in elderly mice, there is an accumulation of dysfunctional tissue-resident memory T cells in the lungs which scientists suggest may drive chronic inflammation and fibrosis.
Researchers have found antibodies, from infection with common cold coronaviruses, can also target SARS-CoV-2 - especially in children.